Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4881159 | 0.89 | TSHR (0.33) | LMNATSHR | |
| SCHEMBL6697084 | 0.88 | ALDH1A1 (0.33) | TSHR | |
| SCHEMBL1680605 | 0.82 | TSHR (0.32) | TSHR | |
| SCHEMBL1680269 | 0.82 | TSHR (0.42) | TSHR | |
| SCHEMBL17819275 | 0.80 | — | — | |
| SCHEMBL17781255 | 0.80 | TSHR (0.33) | TSHR | |
| SCHEMBL692705 | 0.78 | — | — | |
| SCHEMBL1023994 | 0.77 | ALDH1A1 (0.36) | TSHR | |
| SCHEMBL9646025 | 0.77 | ALDH1A1 (0.36) | TSHR | |
| SCHEMBL20165967 | 0.77 | DNM1 (0.33) | TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250109137-A1 | IMIDAZOPYRIDAZINE IL-17 INHIBITOR COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2025-04-03 | — | — | US | disclosed |
| US-12173007-B2 | Imidazopyridazine IL-17 inhibitor compounds | JANSSEN PHARMACEUTICA NV (BE) | 2024-12-24 | — | — | US | disclosed |
| EP-4408847-A1 | IMIDAZOPYRIDAZINE IL-17 INHIBITOR COMPOUNDS | Janssen Pharmaceutica NV (BE) | 2024-08-07 | — | — | EP | disclosed |
| US-20230143050-A1 | IMIDAZOPYRIDAZINE IL-17 INHIBITOR COMPOUNDS | JANSSEN RESEARCH & DEVELOPMENT, LLC | 2023-05-11 | — | — | US | disclosed |
| WO-2023049887-A1 | IMIDAZOPYRIDAZINE IL-17 INHIBITOR COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2023-03-30 | — | — | WO | disclosed |
| US-8841327-B2 | Heterocycles substituted pyridine derivatives and antifungal agent containing thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2014-09-23 | — | — | US | disclosed |
| EP-1944303-B1 | PYRIDINE DERIVATIVE SUBSTITUTED BY HETEROCYCLE AND FUNGICIDE CONTAINING THE SAME | EISAI R&D MAN CO LTD (JP) | 2013-08-21 | — | — | EP | disclosed |
| US-8507530-B2 | Pyridine derivatives substituted by heterocyclic ring and phosphonoamino group, and anti-fungal agent containing same | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2013-08-13 | — | — | US | disclosed |
| EP-1867650-B1 | HYDROXYMETHYLBORON COMPOUNDS | EISAI R&D MAN CO LTD (JP) | 2012-06-27 | — | — | EP | disclosed |
| US-8158657-B2 | Heterocycles substituted pyridine derivatives and antifungal agent containing thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-04-17 | — | — | US | disclosed |
| EP-2017275-A1 | BENZISOXAZOLE COMPOUND | Eisai R&D Management Co., Ltd. (JP) | 2009-01-21 | — | — | EP | disclosed |
| US-20080242859-A1 | Oxymethyl Boron Compounds | EISAI R&D MANAGEMENT CO., LTD (JP) | 2008-10-02 | — | — | US | disclosed |
| EP-1944303-A1 | PYRIDINE DERIVATIVE SUBSTITUTED BY HETEROCYCLE AND FUNGICIDE CONTAINING THE SAME | Eisai R&D Management Co., Ltd. (JP) | 2008-07-16 | — | — | EP | disclosed |
| EP-1867650-A1 | HYDROXYMETHYLBORON COMPOUNDS | Eisai R&D Management Co., Ltd. (JP) | 2007-12-19 | — | — | EP | disclosed |
| EP-1864980-A1 | ANTIFUNGAL AGENT CONTAINING PYRIDINE DERIVATIVE | Eisai R&D Management Co., Ltd. (JP) | 2007-12-12 | — | — | EP | disclosed |
| US-20070105904-A1 | 3-(3-(4-(pyridin-2-yloxymethyl)-benzyl)-isoxazol-5-yl)-pyridin-2-ylamine; inhibiting fungal GPI biosynthesis thereby inhibiting expression of cell wall proteins and blocking cell wall assembly while preventing the fungus from attaching to cells | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2007-05-10 | — | — | US | disclosed |
| US-20070105943-A1 | Novel antifungal agent containing heterocyclic compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2007-05-10 | — | — | US | disclosed |
| EP-1782811-A1 | NOVEL ANTIMALARIA AGENT CONTAINING HETEROCYCLIC COMPOUND | Eisai R&D Management Co., Ltd. (JP) | 2007-05-09 | — | — | EP | disclosed |
| EP-1669348-A1 | NOVEL ANTIFUNGAL AGENT COMPRISING HETEROCYCLIC COMPOUND | Eisai Co., Ltd. (JP) | 2006-06-14 | — | — | EP | disclosed |
| WO-2004011427-A2 | SUBSTITUTED BENZANILIDES AS MODULATORS OF THE CCR5 RECEPTOR | SMITHKLINE BEECHAM CORPORATION (US) | 2004-02-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12173007-B2 | Imidazopyridazine IL-17 inhibitor compounds | IL17A, IL23R, IL15 | LMNA 4729/4885TSHR 791/4885 |
| US-20070105943-A1 | Novel antifungal agent containing heterocyclic compound | ERG28, DPM1, CYP51A1 | LMNA 2208/4885TSHR 3952/4885 |
| US-20070105904-A1 | 3-(3-(4-(pyridin-2-yloxymethyl)-benzyl)-isoxazol-5-yl)-pyridin-2-ylamine; inhibiting fungal GPI biosynthesis thereby inhibiting expression of cell wall proteins and blocking cell wall assembly while preventing the fungus from attaching to cells | GPI, ERG28, MAN2A1 | LMNA 2506/4885TSHR 2534/4885 |
| US-20080242859-A1 | Oxymethyl Boron Compounds | BPGM, DDT, DBN1 | LMNA 4472/4885TSHR 3597/4885 |
| US-20230143050-A1 | IMIDAZOPYRIDAZINE IL-17 INHIBITOR COMPOUNDS | IL17A, IL23R, IL15 | LMNA 4729/4885TSHR 791/4885 |
| US-20250109137-A1 | IMIDAZOPYRIDAZINE IL-17 INHIBITOR COMPOUNDS | IL17A, IL23R, IL15 | LMNA 4729/4885TSHR 791/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.